The drug treatment of duodenal ulcer: physiological considerations in the choice of therapy.
D000535:Aluminum / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D015232:Dinoprostone; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000503:physiopathology; D009853:Omeprazole; D009942:Organometallic Compounds; D010276:Parasympatholytics / Q000627:therapeutic use; D011458:Prostaglandins E / Q000627:therapeutic use; D013392:Sucralfate; D014299:Trimipramine / Q000627:therapeutic use
D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D010276:Parasympatholytics; D011458:Prostaglandins E; D013392:Sucralfate; D014299:Trimipramine; D000535:Aluminum; C002791:bismuth tripotassium dicitrate; D015232:Dinoprostone; D009853:Omeprazole; D002229:Carbenoxolone; D001729:Bismuth